Priority areas for cannabis and cannabinoid product research in South Africa

Augustine, Tanya N. ; Cairns, Carel J. ; Chetty, Sean ; Dannatt, Lisa G. ; Gravett, Nadine ; Grey, Glenda ; Grobler, Gerhard ; Jafta, Zukiswa ; Kamerman, Peter ; Lopes, John ; Matsabisa, Motlalepula G. ; Mugabo, Pierre ; Mulder, Michelle ; Parry, Charles ; Rataemane, Solomon ; Siegfried, Nandi ; Steenkamp, Vanessa ; Thomas, Eileen ; Van Zyl-Smit, Richard (2018-06)

CITATION: Augustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.

The original publication is available at https://phcfm.org/index.php/phcfm

Article

The legalisation of cannabis for medicinal use is a contentious space both politically and in the medical community. In 2014, the Medical Innovation Bill introduced by Mario Oriani-Ambrosini MP, aimed to shift the political and legal positions of cannabis as an illegal substance to one available for research and medical use. To date, progress on this has been slow. Cannabis and cannabinoid products are currently available for medicinal use in several countries, including the Netherlands and 29 states in the United States. Locally, anecdotal reports suggest that many of our patients with chronic medical conditions are using cannabis and cannabis-derived or cannabinoid products for symptom alleviation.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/106424
This item appears in the following collections: